Sign Out
Clear to slightly opalescent, colourless to slightly yellow, sterile liquid for intravenous (i.v.) infusion.
MVASI is supplied in 100 mg preservative-free, single-use vials to deliver 4 ml of MVASI (25 mg/ml).
MVASI is supplied in 400 mg preservative-free, single-use vials to deliver 16 ml of MVASI (25 mg/ml).
Active ingredient: Bevacizumab (humanised anti-VEGF monoclonal antibody).
MVASI is a biosimilar medicine to the reference product AVASTIN (bevacizumab). The evidence for comparability supports the use of MVASI for the listed indications.
Sterile/Radioactive Statement: Sterile.
Excipients/Inactive Ingredients: Trehalose dihydrate, Sodium phosphate, Polysorbate, Water for injections.
Continue with Google